Banisteriopsis caapi (Banisteriopsis caapi): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does Banisteriopsis caapi work in the brain?

Banisteriopsis caapi contains beta-carboline alkaloids—primarily harmine, harmaline, and tetrahydroharmine—that act as reversible monoamine oxidase inhibitors (MAOIs). These compounds inhibit MAO-A enzymes in the brain, preventing the breakdown of neurotransmitters like serotonin, dopamine, and norepinephrine. This MAO inhibition allows DMT (when combined in ayahuasca) to remain orally active and contributes to the vine's reported effects on mood and movement disorders. Evidence level: C.

Can you take Banisteriopsis caapi with antidepressants?

No. Combining Banisteriopsis caapi with antidepressants—particularly SSRIs, SNRIs, or MAOIs—can cause life-threatening serotonin syndrome. The vine's MAO-inhibiting compounds prevent serotonin breakdown, and when combined with serotonergic medications, serotonin levels can rise to dangerous levels. Symptoms include agitation, rapid heart rate, high blood pressure, fever, and potentially death. This combination is absolutely contraindicated. A minimum 2-week washout period after stopping antidepressants is typically recommended before any exposure. Evidence level: C.

What is the proper dosage of Banisteriopsis caapi?

Banisteriopsis caapi has no standardized therapeutic dosage and is traditionally used only in ceremonial contexts under the guidance of trained practitioners. The vine's MAO-inhibiting properties make self-administration dangerous. In clinical research settings investigating depression or Parkinson's disease, dosages have varied widely based on preparation method and alkaloid concentration. Those seeking therapeutic benefits should only pursue this under professional supervision in legal, controlled settings. Evidence level: Traditional/C.

Is Banisteriopsis caapi safe during pregnancy or breastfeeding?

No. Banisteriopsis caapi is considered unsafe during pregnancy and breastfeeding. The MAO-inhibiting compounds can cross the placenta and affect fetal development. Additionally, the significant cardiovascular effects and potential for hypertensive episodes pose risks to both mother and fetus. Traditional Amazonian use typically excludes pregnant women from ayahuasca ceremonies. Those who are pregnant, planning pregnancy, or breastfeeding should avoid this herb entirely. Evidence level: C.

What foods should be avoided with Banisteriopsis caapi?

Due to its MAO-inhibiting properties, Banisteriopsis caapi requires avoiding tyramine-rich foods to prevent hypertensive crisis. Restricted foods include aged cheeses, cured meats, fermented foods, soy products, red wine, and certain beers. Stimulants including caffeine, amphetamines, and cocaine are also contraindicated as they can cause dangerous blood pressure spikes. These dietary restrictions should be followed for at least 24-48 hours before and after exposure. Evidence level: C.

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Banisteriopsis caapi is a South American vine used traditionally as a medicinal tea and as a primary component of the psychedelic brew ayahuasca [PMID:38868739, PMID:26976063].

Background

Banisteriopsis caapi is a woody liana indigenous to the Amazon basin [PMID:30713897, PMID:20219660]. It is often combined with Psychotria viridis to create ayahuasca, though it is also used alone in some traditions [PMID:29366418, PMID:32985365].

Traditional uses

Indigenous groups in the Amazon use the plant for healing, spiritual exploration, religious rituals, and spirit communication [PMID:29366418, PMID:39564645]. Specifically, the Piaroa of Southern Venezuela use it to heighten empathy, as a stimulant, and as a hunting aid [PMID:19004422]. It is also used by the Awajún in Peru as an initiation rite via a decoction called purgahuasca [PMID:32985365].

Active compounds

The plant contains beta-carboline alkaloids, specifically harmine, harmaline, and tetrahydroharmine [PMID:32660098, PMID:30488498, PMID:28706205].

Mechanism of action

The beta-carboline alkaloids in B. caapi act as monoamine oxidase (MAO) inhibitors [PMID:31134518, PMID:26976063]. This inhibition prevents the degradation of N,N-dimethyltryptamine (DMT) when consumed as ayahuasca [PMID:38985012]. Additionally, its alkaloids may stimulate adult neurogenesis in vitro [PMID:28706205] and may increase norepinephrine concentration in the Locus coeruleus to reduce neuroinflammation [PMID:39244172].

Clinical evidence

Evidence BDepression

Randomized placebo-controlled clinical trials indicate significant and rapid antidepressant effects, starting as early as 1 day after intervention [PMID:34761362].

Evidence DParkinson's Disease

B. caapi extract improved motor disability in MPTP-treated common marmosets at doses of 56.8 and 113.6 mg/kg [PMID:29368409]. Historical reports from 1929 suggested use of 'banisterine' (harmine) for postencephalitic parkinsonism [PMID:1742748].

Evidence CSubstance Use Disorders

Evidence suggests potential for treating substance use disorders, including alcohol use disorder [PMID:26976063, PMID:39523057].

Evidence BAnxiety

A double-blind, placebo-controlled study on Santo Daime members investigated effects on anxiety and hopelessness, though the provided abstract does not specify the final outcome of the psychometric measures [PMID:17532158].

Safety & adverse effects

Human experimental and naturalist studies suggest a good safety and tolerability profile [PMID:39564645]. However, anecdotal reports include physical and psychological harm [PMID:38868739], and one case report describes acute intoxication in a patient with schizophrenia leading to personal injury and property damage [PMID:2968 la8363]. In vitro studies show harmine can decrease cell viability and increase necrotic cells in microglial cells at concentrations of 75.5-302 µM [PMID:35458698].

Evidence summary

The evidence consists primarily of reviews, historical accounts, and animal/in vitro studies (Level C and D), with some encouraging results from small-scale clinical trials for depression (Level B).

PubMed sources

1.PMID: 38868739 (2023) — Ayahuasca: A review of historical, pharmacological, and therapeutic aspects. · PCN reports : psychiatry and clinical neurosciences
2.PMID: 29366418 (2019) — Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. · Current neuropharmacology
3.PMID: 34761362 (2022) — Ayahuasca for the Treatment of Depression. · Current topics in behavioral neurosciences
4.PMID: 31134518 (2019) — Ayahuasca: Uses, Phytochemical and Biological Activities. · Natural products and bioprospecting
5.PMID: 26976063 (2016) — Ayahuasca: Pharmacology, neuroscience and therapeutic potential. · Brain research bulletin

Banisteriopsis caapi

Sources & Citations

Calculate a safe dose of Banisteriopsis caapi

He Huan Hua TCM

Xiao Yao San Patent

Corynanthe yohimbe

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources

Banisteriopsis caapi

Sources & Citations

Calculate a safe dose of Banisteriopsis caapi

Related Herbs

He Huan Hua TCM

Xiao Yao San Patent

Corynanthe yohimbe

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources